

REMARKS

Claims 23, 28, 33, 34, 38, 39 and 43 are currently amended. New claims 45 and 46 are added. It is respectfully submitted that the present amendment presents no new issues or new matter and places this case in condition for allowance. Reconsideration of the application in view of the above amendments and the following remarks is requested.

I. The Rejection of Claims 23, 25, 26, 28, 33 and 34 under 35 U.S.C. 112 (Written Description)

Claims 23, 28, 33, and 34 are currently amended. Reconsideration of this rejection is requested in light of the amendments above and remarks submitted on 30 July 2009.

II. The Rejection of Claims 38, 39, 43, 44 under 35 U.S.C. 112 (Indefiniteness)

Claims 38, 39 and 43 are currently amended. Reconsideration is requested in light of the amendments above.

III. The Rejection of Claims 23, 25, 26 and 28 under 35 U.S.C. 102

Reconsideration is requested in light of the amendment above.

IV. The Rejection of Claims 30, 31, 33, 34, 36, 41 and 42 under 35 U.S.C. 103

Claims 30, 31, 33, 34, 36, 41 and 42 stand rejected under 35 U.S.C. 103 as allegedly being unpatentable over Lesley et al., Protein Eng. 15, pp. 153-160 (2002) ("Lesley") or Waldo, Curr. Opin. Chem. Biol., 7, pp. 33-38 (2003) ("Waldo") in view of Noone, J. Bacteriol., 183(2), pp. 654-663 (2001) ("Noone").

Reconsideration is requested in light of the amendments above.

V. New Claims

New claims 45 and 46 are added. No new matter is added. Consideration is urged. Should any additional fees be due the USPTO is authorized to charge the deposit account of Novozymes North America, Inc. --Deposit Account no. 50-1701.

VI. Conclusion

In view of the above, it is respectfully submitted that all claims are in condition for allowance. Early action to that end is respectfully requested. The Examiner is hereby invited to

contact the undersigned by telephone if there are any questions concerning this amendment or application.

All required fees were charged to Novozymes North America, Inc.'s Deposit Account No. 50-1701 at the time of electronic filing. The USPTO is authorized to charge this Deposit Account should any additional fees be due.

Respectfully submitted,

Date: May 10, 2010

/Michael W. Krenicky, Reg. # 45411/

Michael W. Krenicky, Reg. No. 45,411
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097